Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Riadh Gouider

Showing results (71-80 of 117) with videos related to

Pageof 12
Sort By:
CNS Drugs|January 27, 2026
Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS GuidelinesBassem Yamout, Riadh Gouider, Raed Al-Roughani, et al.
The Lancet. Neurology|February 21, 2026
Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGADDalia L Rotstein, Raed Alroughani, Georgina Arrambide, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|May 13, 2022
Phylogenetic and amino acid signature analysis of the SARS-CoV-2s lineages circulating in TunisiaMouna Ben Sassi, Sana Ferjani, Imen Mkada, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2024
Safety and effectiveness of disease-modifying therapies after switching from natalizumabMaya Zeineddine, Raed Al-Roughani, Samar Farouk Ahmed, et al.
Neurology|March 6, 2024
Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based StudyTim Spelman, Gabrielle Simoneau, Robert Hyde, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|August 30, 2021
Clinical management and disease-modifying treatment for amyotrophic lateral sclerosis in African hospital centers: the TROPALS studyJaime Luna, Jeremy Jost, Mouhamadou Diagana, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 23, 2018
Clinical features and prognosis of amyotrophic lateral sclerosis in Africa: the TROPALS studyJaime Luna, Mouhamadou Diagana, Leila Ait Aissa, et al.
Frontiers in Neurology|February 7, 2025
Long-term safety of dexamethasone sodium phosphate encapsulated in autologous erythrocytes in pediatric patients with ataxia telangiectasiaMary Kay Koenig, Vincenzo Leuzzi, Riadh Gouider, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 1, 2025
Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched studyBassem Yamout, Raed Alroughani, Samar Frouk Ahmed Mohamed, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 13, 2026
The real-world effectiveness and safety of off-label rituximab in a large cohort of Middle Eastern multiple sclerosis patientsGhida Ismail, Maya Zeineddine, Raed Al-Roughani, et al.
Pageof 12

Showing results (71-80 of 117) with videos related to

Sort By:
Pageof 12
CNS Drugs|January 27, 2026
Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS GuidelinesBassem Yamout, Riadh Gouider, Raed Al-Roughani, et al.
The Lancet. Neurology|February 21, 2026
Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGADDalia L Rotstein, Raed Alroughani, Georgina Arrambide, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|May 13, 2022
Phylogenetic and amino acid signature analysis of the SARS-CoV-2s lineages circulating in TunisiaMouna Ben Sassi, Sana Ferjani, Imen Mkada, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2024
Safety and effectiveness of disease-modifying therapies after switching from natalizumabMaya Zeineddine, Raed Al-Roughani, Samar Farouk Ahmed, et al.
Neurology|March 6, 2024
Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based StudyTim Spelman, Gabrielle Simoneau, Robert Hyde, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|August 30, 2021
Clinical management and disease-modifying treatment for amyotrophic lateral sclerosis in African hospital centers: the TROPALS studyJaime Luna, Jeremy Jost, Mouhamadou Diagana, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 23, 2018
Clinical features and prognosis of amyotrophic lateral sclerosis in Africa: the TROPALS studyJaime Luna, Mouhamadou Diagana, Leila Ait Aissa, et al.
Frontiers in Neurology|February 7, 2025
Long-term safety of dexamethasone sodium phosphate encapsulated in autologous erythrocytes in pediatric patients with ataxia telangiectasiaMary Kay Koenig, Vincenzo Leuzzi, Riadh Gouider, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 1, 2025
Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched studyBassem Yamout, Raed Alroughani, Samar Frouk Ahmed Mohamed, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 13, 2026
The real-world effectiveness and safety of off-label rituximab in a large cohort of Middle Eastern multiple sclerosis patientsGhida Ismail, Maya Zeineddine, Raed Al-Roughani, et al.
Pageof 12